Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: IRELAND

Sector: Biotechnology

Jazz Pharmaceuticals Public Limited Company is a specialty biopharmaceutical company focused on improving patients" lives by identifying, developing and commercializing innovative products that address unmet medical needs. The Company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.
Website: jazzpharma.com


  • Bad financial results growth rate -34.5% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-8.4%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -2.1% (LTM)
  • Share price is 70.1% higher than minimum and 8.0% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 21.7x)
  • For the last 3 months insiders sold company shares on $22.0 mln (-0.198% of cap.)

Key Financials (Download financials)

Ticker: JAZZ
Share price, USD:  (0.0%)166.35
year average price 133.49  


year start price 133.96 2025-02-14

min close price 97.78 2025-05-09

max close price 180.90 2025-11-24

current price 166.35 2026-02-14
Common stocks: 62 442 504

Dividend Yield:  0.0%
Last revenue growth (y/y):  +6.7%
Last growth of EBITDA (y/y):  -75.7%
Historical revenue growth:  +5.0%
Historical growth of EBITDA:  -21.9%
EV / Sales: 3.3x
Margin (EBITDA LTM / Revenue): -5.4%

Target EV / EBITDA (hist percentile): 21.7x
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 10 387
Net Debt ($m): 3 369
EV (Enterprise Value): 13 756
EBITDA LTM (млн $): -223
Price to Book: 2.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-13seekingalpha.com

Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-12globenewswire.com

Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer

2025-12-17prnewswire.com

Jazz Pharmaceuticals to Participate in Upcoming Investor Events

2025-12-05fxempire.com

Trials, Sales Wins Sends Jazz Pharmaceuticals Higher

2025-12-02seekingalpha.com

Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

2025-11-11prnewswire.com

Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025

2025-11-06zacks.com

JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View

2025-11-05seekingalpha.com

Jazz Pharmaceuticals plc (JAZZ) Q3 2025 Earnings Call Transcript

2025-11-05zacks.com

Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat Estimates

2025-10-22prnewswire.com

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-06 2024-11-07 2024-08-01 2024-05-02 2023-11-08 2023-08-09 2023-05-10 2022-11-09
acceptedDate 2025-11-05 16:12:09 2025-08-06 07:33:51 2025-02-26 07:34:03 2024-11-07 07:32:06 2024-08-01 07:33:41 2024-05-02 07:38:51 2024-04-26 16:39:26 2023-11-08 16:11:16 2023-08-09 16:10:24 2023-05-10 16:12:16 2023-03-01 16:16:47 2022-11-09 16:13:13 2022-03-01 16:17:19 2021-02-23 16:48:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 1 126M 1 046M 4 069M 1 055M 1 024M 902M 3 834M 972M 957M 893M 3 659M 941M 3 094M 2 364M
costOfRevenue 258M 116M 446M 112M 265M 251M 436M 102M 98M 129M 541M 134M 441M 149M
grossProfit 868M 929M 3 623M 943M 759M 651M 3 399M 870M 860M 764M 3 119M 807M 2 653M 2 215M
grossProfitRatio 0.771 0.889 0.894 0.741 0.721 0.895 0.898 0.856 0.858
researchAndDevelopmentExpenses 241M 190M 884M 200M 221M 223M 850M 234M 209M 189M 590M 149M 506M 335M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 531M 358M 1 385M 326M 339M 352M 1 343M 308M 341M 298M 1 417M 358M 1 452M 854M
otherExpenses 39M 1 067M 637M 157M -155M 389M 627M 389M 361M 150M 1 177M 141M 526M 647M
operatingExpenses 811M 1 616M 2 907M 683M 559M 575M 2 820M 698M 702M 637M 3 184M 649M 2 483M 1 837M
costAndExpenses 1 069M 1 732M 3 352M 795M 824M 826M 3 256M 800M 800M 766M 3 725M 782M 2 924M 1 985M
interestIncome 0 0 0 0 0 0 0 19M 15M 0 0 0 0 0
interestExpense 49M 47M 238M 59M 62M 66M 289M 71M 73M 74M 288M 80M 279M 100M
depreciationAndAmortization 178M 174M 660M 165M 163M 163M 639M 163M 160M 151M 629M 149M 552M 278M
ebitda 236M -514M 1 522M 425M 362M 240M 1 449M 335M 317M 277M 1 469M 307M 1 028M 1 044M
ebitdaratio 0.209 -0.492 0.403 0.354 0.266 0.345 0.331 0.31 0.327
operatingIncome 58M -686M 717M 260M 199M 76M 579M 172M 158M 126M -66M 158M 170M 378M
operatingIncomeRatio 0.051 -0.656 0.247 0.195 0.084 0.177 0.165 0.141 0.168
totalOtherIncomeExpensesNet -48M -49M -248M -59M -62M -78M -284M -1M -2M -71M -317M -219M -284M -106M
incomeBeforeTax 9M -736M 469M 201M 138M -2M 295M 100M 82M 55M -383M -60M -114M 272M
incomeBeforeTaxRatio 0.008 -0.703 0.19 0.135 -0.002 0.102 0.085 0.062 -0.064
incomeTaxExpense -242M -17M -91M -15M -31M 12M -120M -47M -24M -15M -159M -43M 216M 34M
netIncome 251M -718M 560M 215M 169M -15M 415M 147M 104M 69M -224M -17M -329M 239M
netIncomeRatio 0.223 -0.687 0.204 0.165 -0.016 0.151 0.109 0.078 -0.018
eps 4.14 -11.74 9.06 3.52 2.68 -0.23 6.55 2.33 1.63 1.09 -3.58 -0.27 -5.51 4.28
epsdiluted 4.08 -11.74 3.42 2.42 -0.23 2.06 1.52 1.04 -0.27
weightedAverageShsOut 61M 61M 62M 61M 63M 63M 63M 63M 74M 63M 63M 63M 60M 56M
weightedAverageShsOutDil 62M 61M 66M 63M 70M 63M 72M 71M 74M 74M 63M 63M 60M 57M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-04-26 2023-03-01 2022-03-01 2021-02-23
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -238M -289M -288M -279M -100M
ebit 862M 811M 839M 475M 765M
nonOperatingIncomeExcludingInterest -145M -232M -905M -305M -387M
netIncomeFromContinuingOperations 560M 415M -224M -330M 239M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions -11M -25M 0 0 0
bottomLineNetIncome 571M 440M -224M -330M 239M
epsDiluted 8.65 6.1 -3.58 -5.51 4.22

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-06 2024-11-07 2024-08-01 2024-05-02 2023-11-08 2023-08-09 2023-05-10 2022-11-09
acceptedDate 2025-11-05 16:12:09 2025-08-06 07:33:51 2025-02-26 07:34:03 2024-11-07 07:32:06 2024-08-01 07:33:41 2024-05-02 07:38:51 2024-04-26 16:39:26 2023-11-08 16:11:16 2023-08-09 16:10:24 2023-05-10 16:12:16 2023-03-01 16:16:47 2022-11-09 16:13:13 2022-03-01 16:17:19 2021-02-23 16:48:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 1 236M 1 190M 2 413M 2 218M 1 296M 1 233M 1 506M 1 336M 1 282M 1 168M 881M 839M 591M 1 058M
shortTermInvestments 810M 480M 580M 400M 685M 585M 120M 250M 80M 0 0 60M 0 1 075M
cashAndShortTermInvestments 2 046M 1 670M 2 993M 2 618M 1 981M 1 818M 1 626M 1 586M 1 362M 1 168M 881M 899M 591M 2 133M
netReceivables 764M 714M 717M 724M 698M 707M 706M 628M 610M 624M 651M 601M 563M 396M
inventory 483M 505M 480M 539M 543M 577M 597M 612M 657M 675M 714M 728M 1 073M 95M
otherCurrentAssets 462M 462M 262M 509M 460M 258M 321M 101M 73M 245M 267M 45M 252M 152M
totalCurrentAssets 3 756M 3 350M 4 629M 4 390M 3 496M 3 361M 3 435M 3 246M 3 010M 2 785M 2 606M 2 572M 2 611M 2 840M
propertyPlantEquipmentNet 250M 248M 227M 254M 242M 228M 235M 288M 298M 303M 301M 290M 343M 257M
goodwill 1 827M 1 844M 1 716M 1 805M 1 736M 1 739M 1 753M 1 705M 1 743M 1 723M 1 693M 1 593M 1 828M 958M
intangibleAssets 4 566M 4 769M 4 756M 5 144M 5 079M 5 235M 5 418M 5 418M 5 706M 5 764M 5 794M 5 570M 7 152M 2 195M
goodwillAndIntangibleAssets 6 393M 6 613M 6 472M 6 949M 6 815M 6 975M 7 171M 7 123M 7 448M 7 488M 7 487M 7 163M 8 980M 3 153M
longTermInvestments 4M 4M 4M 0 5M 5M 0 7M 8M 0 0 0 0 0
taxAssets 846M 603M 560M 583M 545M 508M 478M 464M 430M 399M 376M 315M 311M 255M
otherNonCurrentAssets 107M 125M 120M 80M 258M 251M 74M 76M 66M 73M 64M 45M 53M 31M
totalNonCurrentAssets 7 601M 7 594M 7 383M 7 865M 7 866M 7 966M 7 958M 7 958M 8 251M 8 262M 8 229M 7 813M 9 687M 3 696M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 11 356M 10 944M 12 012M 12 256M 11 362M 11 327M 11 393M 11 204M 11 261M 11 047M 10 835M 10 385M 12 299M 6 536M
accountPayables 152M 89M 78M 85M 97M 81M 103M 110M 98M 125M 91M 102M 100M 27M
shortTermDebt 1 043M 1 042M 31M 50M 623M 624M 605M 621M 48M 31M 31M 46M 31M 246M
taxPayables 0 79M 19M 55M 52M 49M 35M 89M 68M 40M 8M 10M 10M 25M
deferredRevenue 0 0 0 0 52M 49M 0 4000 4000 4000 463 000 871 000 2M 3M
otherCurrentLiabilities 1 079M 861M 190M 839M 784M 808M 142M 842M 799M 752M 169M 664M 193M 125M
totalCurrentLiabilities 2 274M 2 071M 1 039M 1 030M 1 556M 1 562M 1 537M 1 573M 945M 909M 933M 813M 809M 654M
longTermDebt 4 385M 4 391M 6 078M 6 152M 5 169M 5 105M 5 108M 5 173M 5 752M 5 762M 5 693M 5 769M 6 019M 1 849M
deferredRevenueNonCurrent 0 0 0 0 68M 56M 0 0 0 0 0 116 000 463 000 2M
deferredTaxLiabilitiesNonCurrent 629M 682M 677M 792M 775M 810M 848M 841M 911M 932M 944M 934M 1 301M 130M
otherNonCurrentLiabilities 109M 94M 87M 111M 99M 97M 105M 127M 127M 109M 107M 6 678M 117M 101M
totalNonCurrentLiabilities 5 123M 5 167M 6 880M 7 055M 6 043M 6 068M 6 120M 6 141M 6 790M 6 803M 6 816M 6 827M 7 524M 2 222M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 53M 69M 54M 90M 85M 56M 79M 79M 83M 72M 88M 88M 103M 154M
totalLiabilities 7 397M 7 238M 7 919M 8 085M 7 599M 7 631M 7 656M 7 715M 7 735M 7 712M 7 750M 7 639M 8 333M 2 876M
preferredStock 0 0 0 0 17M 0 0 0 0 0 0 0 0 0
commonStock 61 000 61 000 61 000 6000 61 000 61 000 61 000 61 000 61 000 61 000 61 000 61 000 61 000 61 000
retainedEarnings 443M 191M 1 127M 936M 871M 864M 879M 884M 812M 803M 734M 974M 830M 1 160M
accumulatedOtherComprehensiveIncomeLoss -569M -486M -948M -603M -888M -882M -842M -1 035M -867M -980M -1 126M -1 618M -400M -134M
othertotalStockholdersEquity 4 086M 4 001M 3 838M 3 780M 3 714M 3 640M 3 581M 3 512M 3 388M
totalStockholdersEquity 3 959M 3 706M 4 094M 4 171M 3 763M 3 696M 3 737M 3 489M 3 526M 3 335M 3 086M 2 745M 3 965M 3 660M
totalEquity 3 959M 3 706M 4 094M 4 171M 3 763M 3 696M 3 737M 3 489M 3 526M 3 335M 3 086M 2 745M 3 965M 3 660M
totalLiabilitiesAndStockholdersEquity 11 356M 10 944M 12 256M 11 362M 11 327M 11 204M 11 261M 11 047M 10 385M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 11 356M 10 944M 12 012M 12 256M 11 362M 11 327M 11 393M 11 204M 11 261M 11 047M 10 835M 10 385M 12 299M 6 536M
totalInvestments 814M 484M 584M 400M 690M 590M 120M 250M 80M 0 0 60M 0 1 075M
totalDebt 5 429M 5 433M 6 162M 6 183M 5 792M 5 785M 5 792M 5 794M 5 800M 5 793M 5 812M 5 815M 6 153M 2 249M
netDebt 4 192M 4 243M 3 749M 3 965M 4 496M 4 552M 4 285M 4 458M 4 518M 4 625M 4 931M 4 975M 5 561M 1 192M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-04-26 2023-03-01 2022-03-01 2021-02-23
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 717M 706M 651M 563M 396M
otherReceivables 0 0 0 0 0
prepaids 177M 185M 92M 131M 62M
totalPayables 97M 138M 98M 110M 52M
otherPayables 19M 35M 8M 10M 25M
accruedExpenses 706M 632M 618M 457M 214M
capitalLeaseObligationsCurrent 15M 19M 16M 16M 14M
capitalLeaseObligationsNonCurrent 39M 59M 72M 87M 140M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 3 914M 3 700M 3 478M 3 535M 2 634M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-06 2024-11-07 2024-08-01 2024-05-02 2023-11-08 2023-08-09 2023-05-10 2022-11-09
acceptedDate 2025-11-05 16:12:09 2025-08-06 07:33:51 2025-02-26 07:34:03 2024-11-07 07:32:06 2024-08-01 07:33:41 2024-05-02 07:38:51 2024-04-26 16:39:26 2023-11-08 16:11:16 2023-08-09 16:10:24 2023-05-10 16:12:16 2023-03-01 16:16:47 2022-11-09 16:13:13 2022-03-01 16:17:19 2021-02-23 16:48:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 251M -718M 560M 215M 169M -15M 415M 147M 104M 69M -224M -20M -330M 239M
depreciationAndAmortization 178M 174M 660M 165M 163M 163M 639M 163M 160M 157M 629M 149M 552M 278M
deferredIncomeTax -271M -66M -208M -64M -75M -66M -260M -79M -79M -66M -292M -65M 69M -137M
stockBasedCompensation 88M 65M 248M 60M 57M 61M 227M 56M 61M 56M 222M 57M 189M 121M
changeInWorkingCapital 131M -327M -77M -30M -27M 56M -204M -25M -17M 18M 10M 70M -48M -85M
accountsReceivables -51M -56M -21M 16M 9M -8M 0 -19M 14M 28M -90M -10M -93M -39M
inventory -32M -26M -46M 18M -5M -13M 0 -5M -816 000 -6M -50M -9M -49M -31M
accountsPayables 62M -13M -20M -13M 15M -20M 10M 10M -27M 34M -11M 29M 57M -19M
otherWorkingCapital 151M -233M 10M -50M -46M 97M -214M -11M -4M -38M 161M 59M 37M 3M
otherNonCashItems 97M 962M 213M 53M 408M 496M 276M 45M 68M 85M 927M 227M 345M 484M
netCashProvidedByOperatingActivities 475M 89M 1 396M 399M 331M 267M 1 092M 307M 297M 321M 1 272M 418M 779M 900M
investmentsInPropertyPlantAndEquipment -45M -13M -38M -11M -7M -7M -24M -4M -6M -5M -498M 5M -28M -379M
acquisitionsNet 0 -858M 0 0 0 0 0 -20M 0 0 53M 0 -6 235M -364M
purchasesOfInvestments -640M 440M -1 305M 705M -330M -375M -390M -190M -80M 0 -61M -300 000 -27M -2 398M
salesMaturitiesOfInvestments 400M 470M 845M 355M 80M 120M 270M 20M 0 0 60M 0 1 095M 1 755M
otherInvestingActivites -43M -680M -835M -250M -10M 20M 0 0 0
netCashUsedForInvestingActivites -328M -641M 214M -257M -272M -174M -86M -5M 5M
debtRepayment -8M -8M 0 -8M -8M -8M -8M -8M -308M
commonStockIssued 733 000 10M -11M 0 494 000 6M 11M 0 0
commonStockRepurchased 0 -125M -311M -150M -161M -49M -270M -74M -96M 0 -54 000 0 0 -147M
dividendsPaid 0 0 0 0 0 -6M -85M 0 0
otherFinancingActivites -4M -2M 396M 11M -49M 4M 81M -22M 19M
netCashUsedProvidedByFinancingActivities -11M -125M 246M -161M -57M -78M -97M -30M -289M
effectOfForexChangesOnCash -90M 5M -2M 3M -759 000 -2M 1M -1M 34 000 331 000 -6M -5M -3M 374 000
netChangeInCash 46M -672M 907M 862M 62M 27M 625M 53M 114M 286M 290M 128M -466M 420M
cashAtEndOfPeriod 1 236M 1 190M 2 413M 2 218M 1 296M 1 233M 1 506M 1 336M 1 282M 1 168M 881M 839M 591M 1 058M
cashAtBeginningOfPeriod 1 190M 1 862M 1 506M 1 296M 1 233M 1 206M 881M 1 282M 1 168M 881M 591M 711M 1 058M 637M
operatingCashFlow 475M 89M 1 396M 399M 331M 267M 1 092M 307M 297M 321M 1 272M 418M 779M 900M
capitalExpenditure -15M 12M -48M -11M -7M -7M -24M -4M -6M -5M -498M 5M -46M -379M
freeCashFlow 459M 101M 1 348M 388M 324M 260M 1 068M 303M 291M 316M 774M 423M 733M 520M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-04-26 2023-03-01 2022-03-01 2021-02-23
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -10M -19M 0 -18M 379M
netCashProvidedByInvestingActivities -508M -163M -446M -5 212M -1 008M
netDebtIssuance 375M -31M -582M 3 871M 592M
longTermNetDebtIssuance 375M -31M -582M 3 871M 592M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -311M -270M 98M 0 -163M
netCommonStockIssuance -311M -270M -54 000 0 -147M
commonStockIssuance 0 0 0 0 0
netPreferredStockIssuance 0 0 98M 0 -17M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -43M -4M -45M 100M 100M
netCashProvidedByFinancingActivities 21M -305M -529M 3 971M 528M
incomeTaxesPaid 115M 178M 95M 271M 227M
interestPaid 315M 333M 271M 138M 42M

Earning call transcript

2025 q3
2025-11-05 ET (fiscal 2025 q3)
2025 q2
2025-08-06 ET (fiscal 2025 q2)
2025 q1
2025-05-06 ET (fiscal 2025 q1)
2024 q4
2025-02-25 ET (fiscal 2024 q4)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q2
2024-07-31 ET (fiscal 2024 q2)
2024 q1
2024-05-01 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-09 ET (fiscal 2023 q2)
2023 q1
2023-05-10 ET (fiscal 2023 q1)
2022 q4
2023-03-01 ET (fiscal 2022 q4)
2022 q3
2022-11-09 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-11-05 16:12 ET
Jazz Pharmaceuticals reported for 2025 q3
SEC form 8
2025-11-05 16:07 ET
Jazz Pharmaceuticals published news for 2025 q3
SEC form 8
2025-11-05 16:07 ET
Jazz Pharmaceuticals reported for 2025 q3
SEC form 10
2025-08-06 11:33 ET
Jazz Pharmaceuticals reported for 2025 q2
SEC form 8
2025-08-05 20:08 ET
Jazz Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-05 20:08 ET
Jazz Pharmaceuticals reported for 2025 q2
SEC form 10
2025-05-07 11:33 ET
Jazz Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-07 00:00 ET
Jazz Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-06 20:08 ET
Jazz Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-06 20:08 ET
Jazz Pharmaceuticals reported for 2025 q1
SEC form 8
2025-04-21 20:14 ET
Jazz Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-21 20:14 ET
Jazz Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-08 21:09 ET
Jazz Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-08 21:09 ET
Jazz Pharmaceuticals published news for 2025 q1
SEC form 8
2025-03-05 21:15 ET
Jazz Pharmaceuticals published news for 2024 q4
SEC form 8
2025-03-05 21:15 ET
Jazz Pharmaceuticals published news for 2024 q4
SEC form 8
2025-03-05 12:09 ET
Jazz Pharmaceuticals published news for 2024 q4
SEC form 8
2025-03-05 12:09 ET
Jazz Pharmaceuticals published news for 2024 q4
SEC form 8
2025-03-05 12:09 ET
Jazz Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-26 12:34 ET
Jazz Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-26 00:00 ET
Jazz Pharmaceuticals reported for 2024 q4
SEC form 8
2025-02-25 00:00 ET
Jazz Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-25 00:00 ET
Jazz Pharmaceuticals reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Jazz Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Jazz Pharmaceuticals published news for 2024 q4
SEC form 10
2024-11-07 07:32 ET
Jazz Pharmaceuticals reported for 2024 q3
SEC form 8
2024-11-06 16:06 ET
Jazz Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-06 16:06 ET
Jazz Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-01 07:33 ET
Jazz Pharmaceuticals published news for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Jazz Pharmaceuticals published news for 2024 q2
SEC form 8
2024-07-31 16:06 ET
Jazz Pharmaceuticals published news for 2024 q2
SEC form 8
2024-07-31 16:06 ET
Jazz Pharmaceuticals reported for 2024 q2
SEC form 10
2024-05-02 07:38 ET
Jazz Pharmaceuticals published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Jazz Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-01 16:06 ET
Jazz Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-01 16:06 ET
Jazz Pharmaceuticals reported for 2024 q1
SEC form 10
2024-02-28 17:03 ET
Jazz Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-28 16:06 ET
Jazz Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-28 16:06 ET
Jazz Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Jazz Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Jazz Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Jazz Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-08 16:11 ET
Jazz Pharmaceuticals reported for 2023 q3
SEC form 8
2023-11-08 16:07 ET
Jazz Pharmaceuticals published news for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Jazz Pharmaceuticals published news for 2023 q3
SEC form 10
2023-08-09 16:10 ET
Jazz Pharmaceuticals reported for 2023 q2
SEC form 6
2023-08-09 16:07 ET
Jazz Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Jazz Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Jazz Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-22 16:05 ET
Jazz Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Jazz Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-10 00:00 ET
Jazz Pharmaceuticals published news for 2023 q1
SEC form 10
2023-03-01 16:16 ET
Jazz Pharmaceuticals reported for 2022 q4
SEC form 6
2023-03-01 16:07 ET
Jazz Pharmaceuticals published news for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Jazz Pharmaceuticals reported for 2022 q4
SEC form 8
2023-03-01 00:00 ET
Jazz Pharmaceuticals reported for 2022 q4
SEC form 6
2023-01-09 07:31 ET
Jazz Pharmaceuticals published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Jazz Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-04 17:25 ET
Jazz Pharmaceuticals published news for 2022 q4
SEC form 6
2022-12-21 07:40 ET
Jazz Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-05 16:16 ET
Jazz Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-14 16:31 ET
Jazz Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-09 16:13 ET
Jazz Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-09 16:07 ET
Jazz Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Jazz Pharmaceuticals reported for 2022 q3
SEC form 8
2022-11-09 00:00 ET
Jazz Pharmaceuticals reported for 2022 q3
SEC form 6
2022-10-19 06:59 ET
Jazz Pharmaceuticals published news for 2022 q3
SEC form 10
2022-08-03 16:22 ET
Jazz Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-03 16:07 ET
Jazz Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Jazz Pharmaceuticals reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Jazz Pharmaceuticals reported for 2022 q2
SEC form 6
2022-06-10 20:04 ET
Jazz Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-31 16:43 ET
Jazz Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-04 16:20 ET
Jazz Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-04 16:17 ET
Jazz Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-04 16:13 ET
Jazz Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Jazz Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Jazz Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-02 16:30 ET
Jazz Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-07 07:15 ET
Jazz Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-28 08:55 ET
Jazz Pharmaceuticals published news for 2021 q4
SEC form 10
2022-03-01 16:17 ET
Jazz Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-01 16:07 ET
Jazz Pharmaceuticals published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
Jazz Pharmaceuticals published news for 2021 q4
SEC form 8
2022-03-01 00:00 ET
Jazz Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-10 07:47 ET
Jazz Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Jazz Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-09 16:12 ET
Jazz Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-09 16:07 ET
Jazz Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Jazz Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Jazz Pharmaceuticals published news for 2021 q3
SEC form 6
2021-09-23 20:10 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-30 10:09 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-19 17:07 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-03 16:37 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-03 16:07 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-28 20:16 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-19 16:03 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-01 17:17 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-11 16:38 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-01 16:16 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-05 16:10 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-04 16:45 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-04 16:08 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-29 16:23 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-23 16:40 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-23 16:26 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-22 17:08 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-20 09:01 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-03-23 16:33 ET
Jazz Pharmaceuticals published news for 2020 q4
SEC form 6
2021-03-22 06:36 ET
Jazz Pharmaceuticals published news for 2020 q4
SEC form 10
2021-02-23 16:48 ET
Jazz Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 16:08 ET
Jazz Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-03 18:41 ET
Jazz Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-03 07:52 ET
Jazz Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-12 16:22 ET
Jazz Pharmaceuticals published news for 2020 q4
SEC form 6
2020-11-17 07:36 ET
Jazz Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-02 16:48 ET
Jazz Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-02 16:11 ET
Jazz Pharmaceuticals published news for 2020 q3